A Randomized Double-Blind Placebo-Controlled Trial of the Effects of Docosahexaenoic Acid (DHA) in Slowing the Progression of Alzheimer's Disease (DHA)

Long Name:A Randomized Double-Blind Placebo-Controlled Trial of the Effects of Docosahexaenoic Acid (DHA) in Slowing the Progression of Alzheimer's Disease (DHA)

The target population is males and females age ≥ 50 years who have a diagnosis of probable Alzheimer’s disease and have a reliable study partner. The goal is to determine whether chronic DHA supplementation slows the progression of cognitive and functional decline over 18 months in mild to moderate Alzheimer’s Disease (AD), as indicated by change in scores on the ADAS-Cog and CDR-SOB. The types of assessments and questionnaires that were obtained include: Medical History, Demographics, height, weight, Vital Signs, Concomitant Medications, cognitive test battery, MMSE, CDR–SB (Clinical Dementia Rating Sum of Boxes) and ADAS-COG(Alzheimer's Disease Assessment Scale-cognitive subscale).

Last Updated: 09-12-2016
Comprehensive Cancer Centers National Designation is RenewedMagnet Hospital RecognitionConsumer Choice2015 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.

© Wake Forest Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC 27157. All Rights Reserved.